Abbott Labs Makes Marketing Push For New Glucose Monitors, Targets Health-Conscious Consumers
Abbott Labs Makes Marketing Push For New Glucose Monitors, Targets Health-Conscious Consumers
Abbott Laboratories (NYSE:ABT) CEO Robert Ford said the company will use a mix of TV advertisements and guerilla marketing to promote the U.S. launch of Lingo, its glucose monitoring device.
Abbott Laboratories（紐交所：ABT）首席執行官Robert Ford表示公司將利用電視廣告和遊擊營銷的混合方式推廣其血糖監測器Lingo的美國上市。
This device targets consumers without diabetes, aiming to personalize health data and enhance understanding of their health metrics.
該設備針對沒有糖尿病的消費者，旨在個性化健康數據並增強對其健康指標的理解。
Also Read: Similac Baby Formula Maker Abbott And Reckitt Face Hundreds Of Baby Formula Lawsuits.
此外還閱讀了：Similac嬰兒奶粉製造商Abbott和Reckitt面臨數百起嬰兒奶粉訴訟。
Ford projected that Lingo could become a multi-billion-dollar product, although it is still in its nascent stage.
Ford預計Lingo可以成爲一個創造數十億美元的產品，儘管它仍處於初期階段。
Lingo, an over-the-counter device, is scheduled to launch this year alongside Libre Rio, which received FDA clearance last month.
場外交易的Lingo計劃在今年上市，與上個月獲得FDA認證的Libre Rio一起推出。
Abbott's consumer biowearable, Lingo, is designed for consumers 18 years and older looking to improve their overall health and wellness.
Abbott的消費者生物可穿戴設備Lingo，旨在面向18歲及以上的消費者，幫助他們改善整體健康和健康狀況。
Lingo will track glucose and provide personalized insights and customized coaching to help people create healthy habits, retrain their metabolism, and improve their overall well-being.
Lingo將跟蹤血糖，並提供個性化見解和定製輔導，幫助人們養成健康的習慣，重新培養代謝，提高整體健康狀況。
Libre Rio Libre Rio will be Abbott's first over-the-counter CGM system for people with diabetes in the U.S.
Libre Rio將成爲Abbott在美國推出的首個場外CGM系統，適用於患有糖尿病的人。
It is designed for people ages 18 and older with Type 2 diabetes who do not use insulin and typically manage their diabetes through lifestyle modifications.
它專爲18歲及以上患有2型糖尿病且不使用胰島素並通常通過生活方式改變管理糖尿病的人設計。
In continuous glucose monitoring, Abbott competes with DexCom Inc (NASDAQ:DXCM) and Medtronic Plc (NYSE:MDT).
在連續血糖監測方面，Abbott與DexCom Inc（納斯達克股票代碼：DXCM）和Medtronic Plc（紐交所股票代碼：MDT）競爭。
During the second quarter, FreeStyle Libre, Abbott's prescription blood sugar monitor, achieved $1.6 billion in global sales, up 18.4% year over year.
在第二季度，Abbott的診方血糖監測儀FreeStyle Libre全球銷售額達到160億美元，同比增長18.4％。
Reuters notes that the company acknowledges that marketing a consumer product like Lingo will differ significantly from promoting a medical device.
據路透社報道，該公司承認推廣像Lingo這樣的消費品與推廣醫療設備有很大不同。
Ford emphasized the importance of guerilla marketing, which includes on-ground outreach and social media campaigns, to drive adoption.
Ford強調了遊擊營銷的重要性，包括現場外聯和社交媒體活動，以推動採用。
Sourcing an RBC Capital Markets analyst, Reuters noted that while current sales projections for Abbott and DexCom's OTC products are modest, the potential market is significant.
援引RBC Capital Markets的一位分析師的話，路透社指出，雖然Abbott和DexCom的場外交易產品目前的銷售預測是適度的，但潛在市場非常大。
Singh highlighted that Abbott is just beginning to launch Lingo this summer, presenting substantial opportunities for both companies.
辛格（Singh）強調，Abbott剛剛開始在今年夏天推出Lingo，爲兩家公司提供了巨大的機會。
Ford anticipates that sales growth for Lingo will gradually increase as Abbott establishes the market and learns from its early efforts.
福特預計，隨着Abbott確立市場並從早期努力中學到經驗，Lingo的銷售增長將逐漸增加。
Price Action: ABT stock is up 1.38% at $101.44 at the last check on Friday.
股票價格：ABT股票在上週五最後一次檢查時上漲了1.38％，至101.44美元。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免責聲明：本內容部分使用人工智能工具生成，並經Benzinga編輯審核發佈。
- Eli Lilly's Famed Weight Loss Drug Zepbound Scores Chinese Approval.
- 禮來公司廣受歡迎的減肥藥Zepbound在中國獲得批准。
Photo via Shutterstock
圖片來自shutterstock。
譯文內容由第三人軟體翻譯。